Laurus Labs Ltd. (LAURUSLABS) Share Price Hits Fresh 52-Week High
- August 5, 2026
- Posted by: Harsh Piplani
- Category: News
Laurus Labs Ltd. Share Price reached a fresh 52-week high of Rs 1,850.3, marking a 0.81% increase today. The company’s market capitalisation stands at Rs 97,850.54 crore.
Laurus Labs Ltd. Share Price has achieved a fresh 52-week high, reaching Rs 1,850.3. The stock experienced a 0.81% increase from its previous close of Rs 1,835.5. With a market capitalisation of Rs 97,850.54 crore, Laurus Labs Ltd. is drawing significant attention in the market. This milestone highlights the stock’s upward momentum, although the data does not specify a company-specific catalyst for this rise. Investors are keenly observing the stock’s performance, given its position in the healthcare sector.
Laurus Labs Ltd. Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,850.3 |
| Previous Close | Rs 1,835.5 |
| Today's Change | +Rs 14.8 (+0.81%) |
| Day Open | Rs 1,858.95 |
| Fresh 52-Week High | Rs 1,858.95 |
| Day Low | Rs 1,844.65 |
| Current Volume | 6,227 |
| Turnover | Rs 1.15 crore |
| Market Capitalisation | Rs 97,850.54 crore |
Laurus Labs Ltd. (LAURUSLABS) traded at Rs 1,850.3. versus the previous close of Rs 1,835.5, a rise of 0.81%. The stock opened at Rs 1,858.95, reached Rs 1,858.95, touched Rs 1,844.65. Reported volume was 6,227.
Today, Laurus Labs Ltd. opened at Rs 1,858.95, reaching a high of Rs 1,858.95 and a low of Rs 1,844.65. The stock’s turnover was Rs 1.15 crore with a volume of 6,227 shares. The fresh 52-week high of Rs 1,858.95 indicates robust trading activity. The stock’s current price of Rs 1,850.3 represents a 0.81% increase from the previous close. This price action suggests strong investor interest, setting the stage for further analysis of its fundamentals.
Laurus Labs Ltd. (LAURUSLABS) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 97,850.54 crore |
| P/E Ratio | 30.21x |
| P/B Ratio | 0.44x |
| ROE | -2.89% |
| ROCE | -0.26% |
Laurus Labs Ltd. was valued at a P/E ratio of 30.21x, a P/B ratio of 0.44x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of -2.89% and ROCE of -0.26%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Benchmark Scope | same sector |
| Company P/E Ratio | 30.21x |
| Benchmark Median P/E | 21.71x |
| Benchmark Average P/E | 71.67x |
| Benchmark P/E Range | 0x to 3,385.56x |
| Company P/B Ratio | 0.44x |
| Benchmark Median P/B | 1.9x |
| Company ROE | -2.89% |
| Benchmark Median ROE | 10.75% |
| Company ROCE | -0.26% |
| Benchmark Median ROCE | 13.29% |
| Company Market Capitalisation | Rs 97,850.54 crore |
| Benchmark Median Market Cap | Rs 136.63 crore |
Laurus Labs Ltd. (LAURUSLABS) is classified under sector: Healthcare.
Laurus Labs Ltd. (LAURUSLABS) has a P/E ratio of 30.21x, which is above the benchmark median of 21.71x, a difference of +39.15%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Laurus Labs Ltd. (LAURUSLABS) has a ROE of -2.89%, which is below the benchmark median of 10.75%, a difference of -126.88%. Laurus Labs Ltd. (LAURUSLABS) has a ROCE of -0.26%, which is below the benchmark median of 13.29%, a difference of -101.96%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,945.17 | 30.21 | 0.44 | -2.89 | -0.26 |
| Kwality Pharmaceuticals Ltd. | KPL | 2,652.68 | 39.86 | 8.11 | 28.21 | 26.35 |
| Beta Drugs Ltd. | BETA | 2,608.51 | 63.2 | 10 | 18.65 | 22.17 |
| Dr Agarwals Eye Hospital Ltd. | DRAGARWQ | 2,457.9 | 32.25 | 6.65 | -2.6 | 16.92 |
| Sai Parenteral's Ltd. | SAIPARENT | 2,451.51 | 164.6 | 3.04 | 13.9 | 12.97 |
Laurus Labs Ltd. (LAURUSLABS) has a P/E ratio of 30.21x compared with the displayed peer median of 39.86x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -2.89% compares with a peer median of 13.9% across the companies shown in the table. ROCE stood at -0.26% versus the displayed peer median of 16.92%, providing a capital-efficiency comparison. Laurus Labs Ltd. (LAURUSLABS) has a market capitalisation of Rs 97,850.54 crore. Among the 5 peers shown, 0 have a larger market capitalisation.
Why Investors Are Watching Laurus Labs Ltd.
- Achieved a fresh 52-week high of Rs 1,850.3.
- Strong trading activity with a 0.81% increase today.
- Market capitalisation of Rs 97,850.54 crore.
- Moderate P/E ratio compared to sector median.
- Negative profitability metrics compared to peers.
About Laurus Labs Ltd.
Laurus Labs Ltd. operates in the healthcare sector, focusing on pharmaceuticals and drugs. The company is involved in the development and manufacturing of active pharmaceutical ingredients (APIs), finished dosage forms (FDFs), and synthesis services. Laurus Labs Ltd. serves various markets, including antiretrovirals, oncology, and other therapeutic areas. Its operations are supported by a robust research and development framework, positioning it as a key player in the pharmaceutical industry.
Track Laurus Labs Ltd. Share Price on Univest
Use Laurus Labs Ltd. (LAURUSLABS) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Investors can track Laurus Labs Ltd. Share Price, technical indicators, fundamental ratios, shareholding pattern, 52-week levels, and market insights on Univest. Stay informed with real-time data and comprehensive analysis.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is Laurus Labs Ltd. Share Price today?
Ans. Laurus Labs Ltd. Share Price today is Rs 1,850.3, marking a 0.81% increase from the previous close of Rs 1,835.5. The stock has reached a fresh 52-week high. The stock moved 0.81% during the session.
How did Laurus Labs Ltd. perform today?
Ans. Laurus Labs Ltd. opened at Rs 1,858.95, reached a high of Rs 1,858.95, and a low of Rs 1,844.65. The stock's turnover was Rs 1.15 crore with a volume of 6,227 shares.
What is Laurus Labs Ltd.'s market capitalisation?
Ans. Laurus Labs Ltd.'s market capitalisation is Rs 97,850.54 crore, reflecting its size and position within the healthcare sector. The company operates in the Healthcare sector. Its P/E ratio is 30.21x.
How does Laurus Labs Ltd.'s P/E ratio compare to the sector?
Ans. Laurus Labs Ltd.'s P/E ratio of 30.21 is above the sector median of 21.71 but below the sector average of 71.67, indicating a moderate valuation. The company trades at a P/E ratio of 30.21x.
What are Laurus Labs Ltd.'s profitability metrics?
Ans. Laurus Labs Ltd. has a negative ROE of -2.89% and a negative ROCE of -0.26%, indicating challenges in profitability compared to sector averages. ROE stands at -2.89%. ROCE stands at -0.26%.
Who are Laurus Labs Ltd.'s peers?
Ans. Laurus Labs Ltd.'s peers include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., Beta Drugs Ltd., Dr Agarwals Eye Hospital Ltd., and Sai Parenteral's Ltd. Comparable listed companies include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., Beta Drugs Ltd.
What is Laurus Labs Ltd.'s P/B ratio?
Ans. Laurus Labs Ltd.'s P/B ratio is 0.44, significantly lower than the sector median of 1.9, suggesting a lower valuation relative to its book value. The company trades at a P/E ratio of 30.21x.
How does Laurus Labs Ltd. compare to its peers?
Ans. Laurus Labs Ltd. shares similar P/E and P/B ratios with Dishman Carbogen Amcis Ltd., but faces profitability challenges compared to peers like Kwality Pharmaceuticals Ltd. and Beta Drugs Ltd. Comparable listed companies include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd..
What is the significance of Laurus Labs Ltd.'s 52-week high?
Ans. Laurus Labs Ltd.'s 52-week high of Rs 1,850.3 highlights strong investor interest and trading activity, marking a significant milestone for the stock. The stock moved 0.81% during the session. The intraday range extended from Rs 1,844.65 to Rs 1,858.95.
